The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4218-4224

  Afsharian, Parvaneh ^a   Terelius, Ylva ^b   Hassan, Zuzana ^a,c   Nilsson, Christina ^a   Lundgren, Stefan ^c   Hassan, Moustapha ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; TREATMENT DURATION;

EID: 34547096973     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0320     Document Type: Article

References (36)

1. Binotto G, Trentin L, Semenzato G. Ifosfamide and cyclophosphamide: effects on immunosurveillance. Oncology 2003;65:17-20.
2. Lindley C, Hamilton G, McCune JS, et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 2002;30:814-22.
3. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988;37:301-55.
4. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-37.
5. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-35.
6. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999;27:655-66.
7. Yu LJ, Drewes P, Gustafsson K, Brain EG, Hecht JE, Waxman DJ. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 1999;288:928-37.
8. Deliliers GL, Annaloro C, Marconi M, et al. Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymphoma 2002;43:1957-60.
9. Ahn JS, Park S, Im SA, et al. High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization. Korean J Intern Med 2005;20:224-31.
10. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-8.
11. Graham MI, Shaw IC, Souhami RL, Sidau B, Harper PG, McLean AE. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother Pharmacol 1983;10:192-3.
12. Fasola G, Lo Greco P, Calori E, et al. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation. Haematologica 1991;76:120-5.
13. Schuler U, Ehninger G, Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol 1987;20:248-52.
14. Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998;64:289-301.
15. Hassan M, Svensson US, Ljungman P, et al. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol 1999;48:669-77.
16. Moore MJ, Hardy RW, Thiessen JJ, Soldin SJ, Erlichman C. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988;44:622-8.
17. McGuire TR, Gwilt P, Manouvilov K, et al. High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. Int Immunopharmacol 2003;3:279-83.
18. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57:1946-54.
19. Gervot L, Rochat B, Gautier JC, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 1999;9:295-306.
20. LeBlanc GA, Waxman DJ. Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Res 1990;50:5720-6.
21. McClure MT, Stupans I. Investigation of the mechanism by which cyclophosphamide alters cytochrome P450 in male rats. Biochem Pharmacol 1992;43:2655-8.
22. McClure MT, Stupans I. Hormonal perturbation as a possible mechanism for the alteration of cytochrome P450 by cyclophosphamide. Biochem Pharmacol 1995;49:1827-36.
23. Angley MT, Sansom LN, Stupans I. Cyclophosphamide given repeatedly to the male rat and as a single dose to the female rat. Its effects on hepatic and pulmonary P450 and associated enzymes. Xenobiotica 1995;25:1051-62.
24. Kraner JC, Morgan ET, Poet TS, Born SL, Burnett VL, Halpert JR. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity. J Pharmacol Exp Ther 1996;276:258-64.
25. Xie H, Afsharian P, Terelius Y, et al. Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat. Xenobiotica 2005;35:239-51.
26. Xie HJ, Broberg U, Griskevicius L, et al. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant 2003;31:197-203.
27. von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H. Drug metabolism in human liver in vitro : establishment of a human liver bank. Clin Pharmacol Ther 1980;27:711-25.
28. Griskevicius L, Meurling L, Hassan M. Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma. Ther Drug Monit 2002;24:405-9.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
30. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
31. Iwanari M, Nakajima M, Kizu R, Hayakawa K, Yokoi T. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol 2002;76:287-98.
32. Edwards RJ, Price RJ, Watts PS, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003;31:282-8.
33. Laslett TJ, Alvarez F, Nation RL, Evans AM, Scott SD, Stupans I. Effect of cyclophosphamide administration on the activity and relative content of hepatic P4502D1 in rat. Xenobiotica 1995;25:1031-9.
34. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-53.
35. Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000;275:15122-7.
36. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320:72-80.